CAR-T后可测量残留病灶监测可早期发现套细胞淋巴瘤复发
该回顾性研究分析37例接受brexu-cel治疗的复发/难治套细胞淋巴瘤患者,采用Ig-HTS监测MRD。第28天MRD可检测者PFS显著劣于不可检测者(10.9 vs 51.5个月),纵向监测在多数复发患者中早于PET/CT约6.5个月发现复发。
要点
- 第28天MRD可检测提示PFS显著更差,可作为早期预后指标。
- 纵向MRD监测可比PET/CT提前中位6.5个月发现复发。
- 第28天PET-CT反应与PFS无显著相关。
核心结论
- 早期及连续MRD监测是brexu-cel治疗套细胞淋巴瘤的敏感预后和监测工具。
- 第28天MRD可作为长期结局的早期预测指标。
研究设计与样本
- 回顾性分析37例接受brexucabtagene autoleucel治疗的复发/难治套细胞淋巴瘤患者。
- 采用外周血单核细胞下一代免疫球蛋白高通量测序(Ig-HTS)检测MRD,时间点为淋巴细胞清除前、输注后1个月和3个月、之后每3个月。
- 37例中36例成功鉴定克隆型。
主要发现
- 接受桥接治疗者淋巴细胞清除前MRD水平较低(337 [0-198 449] vs 21 213 [1-788 251];p=0.04)。
- 淋巴细胞清除前MRD不可检测者PFS有改善趋势(未达到 vs 28.5个月;HR 5.2;p=0.07)。
- 输注后第28天MRD可检测者PFS劣于不可检测者(10.9 vs 51.5个月;HR 3.99;p=0.002)。
- 第28天PET-CT反应与PFS不相关(p=0.35;HR 1.8)。
- 纵向MRD监测在多数复发患者(18例中15例)中比PET/CT提前中位6.5个月发现复发。
临床怎么用
- 对brexu-cel治疗的套细胞淋巴瘤患者,可考虑在第28天检测MRD以早期识别高危复发者。
- 纵向MRD监测有助于比影像学更早发现疾病复发。
局限性
- 回顾性研究,样本量较小(37例)。
- 单中心经验,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR-T surveillance and consolidation strategies. Measurable residual disease (MRD) has emerged as a powerful prognostic biomarker in frontline MCL, but its role after CAR T-cell therapy remains incompletely defined. We retrospectively analyzed 37 patients with r/r MCL treated with brexucabtagene autoleucel (brexu-cel). MRD was assessed using next-generation immunoglobulin high-throughput sequencing (Ig-HTS) of peripheral blood mononuclear cells obtained before lymphodepletion, at 1- and 3-months post-infusion, and every 3 months thereafter. Clonotype identification was successful in 36 of 37 patients. Pre-lymphodepletion MRD levels were lower in patients receiving bridging therapy (337 [0-198 449] vs. 21 213 [1-788 251]; p = 0.04), and MRD undetectability trended toward improved progression-free survival (PFS; unreached vs. 28.5 months; HR 5.2; p = 0.07). Post-infusion, patients with detectable Day 28 MRD had inferior PFS compared with those with undetectable MRD (10.9 vs. 51.5 months; HR 3.99; p = 0.002), whereas Day 28 PET-CT response did not correlate with PFS (p = 0.35; HR 1.8). Longitudinal MRD monitoring identified relapse a median of 6.5 months before PET/CT in most relapsing patients (15 out of 18). Early and serial MRD monitoring is thus a sensitive prognostic and surveillance tool in brexu-cel treated MCL, with Day 28 MRD serving as an early predictor of long-term outcomes.
引用
- Ananth S, Agarwal N, Sahaf B, et al. Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. Am J Hematol. 2026. PMID: 42077190. doi:10.1002/ajh.70343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。